Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medifast, Inc. (“Medifast” or “the Company”) (NYSE: MED). Investors who purchased Medifast securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Medifast has violated federal securities laws.
Investigation Details:
On April 29, 2024, Medifast reported its quarterly earnings and adjusted its earnings per share of $0.66, considerably lower than Wall Street estimates of $0.80 per share and much lower than the same period in the previous year. Following this news, Medifast stock dropped over 22% on April 30, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Medifast securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
MED — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”